SEC Form 3 · accession 0001019687-16-004924
GT Biopharma, Inc. · GTBP
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | holding | — | — | — | 2,441,148 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Convertible notesF1,F4,F2,F3 | $1.25 | holding | — | — | — | — | Feb 15, 2016 | Common Stock | 3,912,447 | — | D |
Explanation of responses
- F1Subject to conversion pursuant to Note Conversion Agreement.
- F2At option of holder.
- F3Subject to extension under certain conditions.
- F4Or 75% of purchase price of next financing if such price under $1.675.
Remarks
Holdings reported herein are the collective holdings of Bristol Investment Fund, Ltd. ("BIF") and Bristol Capital, LLC ("BC"). Paul Kessler, a Director of BIF and Manager of BC, has voting and investment control over the securities held by BIF and BC. As of the date of this filing, BIF holds 2,080,347 shares of the Issuer's common stock, and convertible notes subject to conversion under certain conditions pursuant to a Note Conversion Agreement into a maximum of 3,411,947 shares of the Issuer's common stock; BC holds 360,801 shares of the Issuer's common stock, and convertible notes subject to conversion under certain conditions pursuant to a Note Conversion Agreement into a maximum of 500,500 shares of the Issuer's common stock.